What is the recommended management approach for an adrenal adenoma, including evaluation of hormonal activity, imaging criteria, and treatment options?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Adrenal Adenoma

All patients with an adrenal adenoma ≥1 cm require comprehensive biochemical testing to exclude hormone excess and imaging characterization to assess malignancy risk, with surgical resection indicated for any hormonally active lesion, masses ≥4 cm with concerning features, or growth >5 mm/year. 1, 2

Initial Evaluation Framework

Biochemical Testing (Mandatory for All Adenomas)

Every adrenal adenoma requires screening for three critical hormone excesses 1:

  • Cortisol excess: 1-mg overnight dexamethasone suppression test

    • Cortisol >5.0 mg/dL indicates subclinical Cushing syndrome (SCS)
    • Add low ACTH or low DHEA-S to confirm diagnosis
    • Consider second confirmatory test (2-day low-dose dexamethasone suppression test) 1
  • Aldosterone excess (if hypertensive): Plasma aldosterone-to-renin ratio (PAC/PRA)

    • Ratio >20 requires confirmatory salt loading test
    • Proceed to adrenal venous sampling in patients >40 years to lateralize 1
  • Pheochromocytoma: Plasma fractionated metanephrines and normetanephrines OR 24-hour urinary metanephrines

    • Critical: Must exclude pheochromocytoma before ANY adrenal surgery 1

Imaging Characterization

Non-contrast CT (NCCT) is the first-line imaging study 2:

  • ≤10 HU: Benign lipid-rich adenoma—no further imaging needed regardless of size 2, 1
  • 11-20 HU: Indeterminate—requires additional imaging (adrenal protocol CT with washout, MRI with chemical shift, or PET-CT) 2
  • >20 HU: Suspicious—multidisciplinary discussion for surgery vs. close follow-up 2

Size thresholds matter 2:

  • <4 cm with benign features: Lower malignancy risk (0.5%)
  • 4-6 cm: 6% malignancy risk
  • 6 cm: >25% malignancy risk

Surgical Indications (Definitive)

Proceed with laparoscopic adrenalectomy for 1, 3:

  1. Any hormonally active adenoma:

    • Primary aldosteronism (unilateral source confirmed by AVS)
    • Pheochromocytoma (after 1-3 weeks α-blockade preparation)
    • Overt Cushing syndrome
    • SCS with documented comorbidities (hypertension, diabetes, osteoporosis, worsening metabolic parameters) 1, 4
  2. Size/imaging criteria:

    • Any mass ≥4 cm with concerning radiographic features 1
    • Heterogeneous appearance with NCCT >20 HU 2
  3. Growth on surveillance:

    • Increase ≥5 mm AND >20% increase in maximum diameter 2
    • Growth >8 mm in 12 months 2

Use open adrenalectomy if adrenocortical carcinoma suspected 1

Non-Surgical Management (Surveillance Protocol)

For benign-appearing, non-functional adenomas <4 cm 1, 2, 1:

Imaging follow-up:

  • Repeat imaging at 6-12 months (NCCT or MRI preferred) 2
  • If stable, no further imaging needed after 12 months of stability 2
  • Exception: Older guidelines 1 suggested annual imaging for 1-2 years, but 2025 ESE guidelines 2 indicate single follow-up at 12 months is sufficient

Biochemical follow-up:

  • Annual hormonal testing for up to 5 years 1
  • Risk of developing hormone excess: 17% at 1 year, 29% at 2 years, 47% at 5 years 1

For indeterminate lesions (remain unclear after additional imaging) 2:

  • Multidisciplinary discussion required
  • Options: Surgical resection vs. repeat imaging in 6-12 months
  • Surgery strongly favored if patient <40 years old (higher malignancy risk) 2

Special Populations

Patients <40 years, pregnant, or children 2:

  • Urgent assessment required (higher malignancy risk)
  • MRI preferred over CT to avoid radiation
  • Consider surgery for any lesion not characteristically benign
  • Even benign-appearing lesions warrant single follow-up at 12 months

Patients with extra-adrenal malignancy 2:

  • Up to 70% of indeterminate lesions are malignant in this population
  • Still exclude pheochromocytoma biochemically before biopsy
  • Biopsy only if histologic diagnosis would alter management

Critical Perioperative Considerations

For cortisol-producing adenomas 1:

  • Perioperative glucocorticoid coverage mandatory
  • Continue replacement 6-18 months post-adrenalectomy until HPA axis recovers
  • Test recovery with morning cortisol or cosyntropin stimulation 3

For pheochromocytoma 1, 5:

  • α-blockade for 1-3 weeks preoperatively (selective or non-selective)
  • Long-term follow-up required: 10-15% recurrence rate 1

For primary aldosteronism 1:

  • If bilateral hyperplasia or patient refuses surgery: mineralocorticoid receptor blockers (spironolactone or eplerenone)

Common Pitfalls to Avoid

  1. Never attempt adrenal surgery without excluding pheochromocytoma—can cause fatal intraoperative hypertensive crisis 1

  2. Don't assume large size alone = malignancy—most adenomas >4 cm are benign if HU ≤10 2, 6

  3. Don't skip biochemical testing even if imaging appears benign—27.5% of incidentalomas are functional 4, 7

  4. Don't use laparoscopic approach if adrenocortical carcinoma suspected—requires open en bloc resection at high-volume center 1, 3

  5. Don't forget glucocorticoid replacement after resecting cortisol-producing adenomas—adrenal insufficiency can be life-threatening 1

References

Guideline

the american association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2009

Guideline

imaging of adrenal masses.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Research

Management Approach of Adrenal Incidentaloma.

Journal of laparoendoscopic & advanced surgical techniques. Part A, 2026

Research

Approach to the Patient With Adrenal Incidentaloma.

The Journal of clinical endocrinology and metabolism, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.